News
Moderna, FDA and Covid
Digest more
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
StockStory.org on MSN20h
Why Moderna (MRNA) Stock Is Falling TodayWhat Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...
Moderna expects to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season. About Moderna.
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
Zacks.com on MSN4d
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric PatientsModerna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback